, Volume 120, Issue 2, pp 437-439
Date: 17 Feb 2010

Personal breast: customizing agents and biomarkers for optimal adjuvant endocrine therapy

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Adjuvant endocrine therapy remains the most important systemic intervention recommended to women with breast cancer whose tumors contain the estrogen receptor (ER) or progesterone receptor. Results from over a dozen prospective clinical trials have consistently demonstrated that the incorporation of the third generation aromatase inhibitors (AIs), including anastrozole, letrozole, and exemestane, in the adjuvant setting, instead of or in sequence with tamoxifen, were superior to 5 years of single agent tamoxifen in reducing breast cancer-related relapse or death [1]. In addition to a small superiority in efficacy, AIs are associated with a slightly different safety profile compared to tamoxifen. Biomarkers that could help predict efficacy and safety to specific endocrine interventions or even to specific agents are greatly needed and could be used to personalize various endocrine manipulations for individual women. Predictive biomarkers may be tumor or host specific, and may be determi

This is an invited commentary to article doi:10.1007/s10549-009-0662-0.